title: Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration.
abstract: OBJECTIVE
  To investigate the variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration.
  
  
  METHODS
  Eight graders, who included two TAP-certified ophthalmologists, three other retinal specialists, two fellows in vitreoretinal diseases, and a senior fundus photograph grader, evaluated fluorescein angiograms of six patients treated according to the Treatment for ARMD With Verteporfin (TAP) protocol at a single center. Each patient's baseline angiogram was evaluated to determine whether the CNV lesion was predominantly (> or =50%) classic. For each follow-up angiogram, at 3, 6, 12, and 24 months, the grader was required to determine whether fluorescein leakage was present. Six months after the initial gradings, each reader was again presented with the baseline angiogram for each patient and once again asked to determine whether the CNV lesion was predominantly classic without knowledge of the previous grading. All gradings were performed without knowledge of the clinical course.
  
  
  RESULTS
  In grading initial visit and follow-up visit angiograms, the overall concordance rates were 81% and 82%, respectively. Concordance rates were not statistically different between the group as a whole when compared with the gradings of the two TAP-certified ophthalmologists. When initial visit angiograms were regraded, an intraobserver variability of 17% was noted. Overall, gradings were discordant with the majority opinion in approximately 19% of decisions.
  
  
  CONCLUSIONS
  Considerable variability can be expected in fluorescein angiography interpretation as the results of the TAP investigation are applied to clinical practice.
authors.affiliation: Retina Service, Wills Eye Hospital, 9th and Walnut Streets, Philadelphia, PA 19107, USA. KaiserRick@AOL.com
authors.forename: Richard S
authors.initials: RS
authors.lastname: Kaiser
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Berger
authors.forename: George A
authors.initials: GA
authors.lastname: Williams
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Tolentino
authors.forename: Albert M
authors.initials: AM
authors.lastname: Maguire
authors.forename: Judith
authors.initials: J
authors.lastname: Alexander
authors.forename: Bojidar
authors.initials: B
authors.lastname: Madjarov
authors.forename: Raymond M
authors.initials: RM
authors.lastname: Margherio
mesh_terms: D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D003627:Data Interpretation, Statistical; D005451:Fluorescein Angiography / Q000592:standards*; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000175:diagnosis*; D015588:Observer Variation; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D015203:Reproducibility of Results; D000077362:Verteporfin
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin